Live Market Data: Sun Pharmaceutical Industries Ltd Share Price Surges Today
Sun Pharmaceutical Industries Ltd witnessed a notable 0.33% surge in its share price and is presently trading at 1788.10, captivating the attention of market participants.
Sun Pharmaceutical Industries Share Price Live
SUNPHARMA
Live Sun Pharmaceutical Industries Share Price Chart
Sun Pharmaceutical Industries Performance
Days Range
| Previous Close | ₹1,782.20 |
|---|---|
| Open | ₹1,780.7 |
| Volume | 30,98,469 |
| Day's Range | ₹1,773.50 - ₹1,803.50 |
|---|---|
| 52W Range | ₹1,548.00 - ₹1,916.60 |
| Market Cap | ₹4,27,933.39 Cr |
Sun Pharmaceutical Industries F & O
Sun Pharmaceutical Industries Fundamentals
| ROCE(TTM) | 17.33 |
|---|---|
| P/E Ratio (TTM) | 37.18 |
| P/B Ratio | 5.12 |
| Industry P/E | 33.71 |
| Debt to Equity | 0.06 |
| ROE | 13.74 |
| EPS (TTM) | 52.01 |
| Dividend Yield | 0.9 |
| Book Value | 348.31 |
| Face Value | 1 |
| ROCE(TTM) | 17.33 |
|---|---|
| P/E Ratio (TTM) | 37.18 |
| P/B Ratio | 5.12 |
| Industry P/E | 33.71 |
| Debt to Equity | 0.06 |
| ROE | 13.74 |
|---|---|
| EPS (TTM) | 52.01 |
| Dividend Yield | 0.9 |
| Book Value | 348.31 |
| Face Value | 1 |
Sun Pharmaceutical Industries Financials
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|
| Net Sales | 13,786.07 | 14,405.22 | 15,469.07 | 14,559.75 |
| Expenses | 10,250.29 | 10,680.76 | 11,304.38 | 11,433.06 |
| Profit before tax | 3,172.77 | 4,167.61 | 4,227.16 | 3,551.34 |
| Operating Profit | 2,302.62 | 3,137.09 | 3,401.09 | 2,723.72 |
| Net Profit | 2,302.62 | 3,137.09 | 3,401.09 | 2,723.72 |
| EPS in Rs | 12.87 | 13.00 | 16.01 | 11.30 |
Sun Pharmaceutical Industries Shareholding Pattern
Promoters
54.48%
Retail And Others
8.48%
Foreign Institutional Investors
15.93%
Domestic Institutional Investors
21.11%
About Sun Pharmaceutical Industries
History
Sun Pharmaceutical Industries Ltd was incorporated in 1983 and began its operations in Kolkata with only 5 products to treat psychiatric ailments. They built a compact manufacturing facility for tablets/capsules at Vapi, Gujarat. An administrative office was opened in Mumbai in 1986. By 1987, they had been marketing their products nationwide. In the late 1980s, the company began exporting their products to neighbouring countries. In 1998, they established their first research centre, SPARC, to create a strong base for product development in the following years. In 1994, the company became listed via an IPO. In 2016, Sun Pharma and AstraZeneca Pharma India Ltd began a partnership for the distribution of an innovative Type 2 diabetes medicine named dapagliflozin in India. In the same year, Sun Pharma and the International Centre for Genetic Engineering and Biotechnology (ICGEB) also agreed to together develop a novel drug for dengue. During in 2021, Sun Pharma launched 96 products in the domestic market. It also supplied drugs like Remdesivir, Favipiravir, Hydroxychloroquine (HCQS), and Liposomal Amphotericin B for the treatment of COVID-19 as well as the anti-epileptic Brevipil (Brivaracetam) and FluGuard (Favipiravir).Business Segments
Sun Pharmaceutical Industries Ltd, along with its subsidiaries and associates, is the fourth largest generic pharma company. As of September 2023, the company has a robust global presence with 43 manufacturing facilities across the world. India and the US are two major markets, accounting for more than 60% of the company's revenue in FY 2023. They also have a strong presence in emerging markets such as Russia, Romania, South Africa, Brazil, Mexico, etc. In terms of the share of disease-wise drugs in the total revenue from India in FY 2023, Cardiology solutions contribute 18%, Neuro-Psychiatry 16%, and Gastroenterology 12%, among others. The company manufactures a wide range of pharmaceutical formulations for chronic and acute therapies. This covers generics, complex products, antiretrovirals (ARVs), Active Pharmaceutical Ingredients (APIs) and intermediates, among others. The portfolio is made of over 2,000 high-quality products with multiple dosage forms, including tablets, capsules, injectables, sprays, inhalers, ointments, etc. Sun Pharmaceutical Industries invests around 7-8% of its global revenue every year in research. The R&D capabilities span the development of differentiated products, such as liposomal products, lyophilised injections, inhalers, and nasal sprays, alongside controlled-release dosage forms. Some of the subsidiaries of Sun Pharmaceuticals include Sun Pharma Laboratories Limited, Sun Pharma Holdings, Sun Pharma Distributors Limited, among others.Key Personnel
Dilip Shanghvi, Founder and Managing Director Mr. Shanghvi is the founder of Sun Pharmaceutical Industries Ltd. with extensive experience in the pharmaceutical industry. Starting out as a first-generation entrepreneur, Mr. Shanghvi is today also the Chairman of Sun Pharma Advanced Research Company Ltd and of the Shantilal Shanghvi Foundation.Corporate Actions
Bonus Shares Sun Pharmaceuticals has issued bonus shares once in 2013 at a ratio of 1:1. Stock Split The face value of the stock had been split once in 2010, from ₹5 to ₹1. Buyback The company performed a buyback of shares in July 2016. Mergers and Acquisitions- In FY 2023, Sun Pharma acquired Concert Pharma. Inc. which was developing a treatment for Alopecia Areata.
- Since 2012, the company has acquired 6 companies in order to scale up their operations. Their past acquisitions include Dusa Pharma, Taro Pharma, URL Pharma, Ranbaxy Laboratories, Biosintez and Pola Pharma.
Management Outlook
The management expects global pharmaceutical spending to grow by a CAGR of 3-6% between 2023 and 2027 to reach a total market size of roughly US$ 1.9 trillion. The company also expects the global specialty pharmaceutical solutions market to grow. It already commands 43% of the total pharmaceutical spending globally as of 2022 and is expected to grow to 56% by 2027. Sensing the above shifts, Sun Pharma has continued to expand its global specialty offerings, with a focus on the areas of dermatology, ophthalmology and onco-dermatology. Their investments are designed to acquire products through in-licensing/acquisitions and in-house R&D and build front-end commercial infrastructure for these products.Parent Organisation
Sun Pharma
Managing Director
Kirti Wardhaman Ganorkar
Founded
1993
NSE Symbol
SUNPHARMA
Top Mutual Funds Invested in Sun Pharmaceutical Industries Share
Peer Comparison
| Stocks | LTP (₹) | Market Cap (cr) | 52 Week Low-High (₹) |
|---|---|---|---|
| Divis Laboratories Ltd | 6,531.5 -91.50 (-1.38%) | ₹1,75,833.11 | 5,636.5 - 7,071.5 |
| Torrent Pharmaceuticals Ltd | 4,412.0 -8.90 (-0.20%) | ₹1,49,548.89 | 3,132.7 - 4,712.9 |
| Cipla Ltd | 1,384.3 -17.00 (-1.21%) | ₹1,13,154.89 | 1,165.7 - 1,673.0 |
| Zydus Lifesciences Ltd | 1,089.5 0.50 (0.05%) | ₹1,09,568.82 | 835.5 - 1,115.5 |
| Dr Reddys Laboratories Ltd | 1,278.3 0.10 (0.01%) | ₹1,06,652.47 | 1,148.4 - 1,379.7 |
| Lupin Ltd | 2,257.9 -9.80 (-0.43%) | ₹1,03,704.91 | 1,836.8 - 2,494.0 |
Popular Stocks
Sun Pharmaceutical Industries Latest News
Sun Pharmaceutical Industries Ltd Share Price Today Live Updates: Sun Pharmaceutical Industries Ltd Rallies in Today's Trading
The share price of Sun Pharmaceutical Industries Ltd experienced an impressive 0.77% upswing and is currently trading at 1796.00, indicating strong market sentiment.
Live Updates: Sun Pharmaceutical Industries Ltd Rallies 0.77%, Gains Momentum in Today's Trading Session
Climbing steadily, Sun Pharmaceutical Industries Ltd shares have ascended by 0.77%, reaching the current market price of 1796.00. This ascent signifies increased investor sentiment. The stock has an ROE of 13.7363 and debt to equity ratio of 0.0554.
Sun Pharmaceutical Industries Ltd FAQs
What is the share price of Sun Pharmaceutical Industries Ltd (SUNPHARMA) shares?
Sun Pharmaceutical Industries Ltd (SUNPHARMA) share price as of June 8, 2026, on NSE is Rs 1788.8 (NSE) and Rs 1788.8 (BSE) on BSE.
Can I buy Sun Pharmaceutical Industries Ltd (SUNPHARMA) from Angel One?
Yes, You can buy Sun Pharmaceutical Industries Ltd (SUNPHARMA) shares by opening a Demat account with Angel One.
How do I buy Sun Pharmaceutical Industries Ltd (SUNPHARMA) from Angel One?
Sun Pharmaceutical Industries Ltd (SUNPHARMA) share can be bought through the following modes:
1. Direct investment: You can buy Sun Pharmaceutical Industries Ltd (SUNPHARMA) shares by opening a Demat account with Angel One.
2. Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to Sun Pharmaceutical Industries Ltd (SUNPHARMA) shares.
1. Direct investment: You can buy Sun Pharmaceutical Industries Ltd (SUNPHARMA) shares by opening a Demat account with Angel One.
2. Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to Sun Pharmaceutical Industries Ltd (SUNPHARMA) shares.
Who are the promoters of Sunpharma?
The promoters of Sunpharma are Shanghvi Finance Private Limited, Dilip.S.Shanghvi, Dilip Shantilal Shanghvi, Aditya Medisales Limited, Raksha S.Valia and Sudhir V. Valia.
What is the main business of Sunpharma?
Sunpharma provides a range of over-the-counter (OTC)/consumer healthcare products.
What are the Brands that comes under Sunpharma?
Being a maker of over-the-counter (OTC)/consumer healthcare products including Faringosept (sore throat), Revital (vitamins) and Volini (topical analgesics). These are a few of their flagship OTC brands that are marketed globally.
What is the market cap of Sun Pharmaceutical Industries?
The market cap of Sun Pharmaceutical Industries is Rs. 427933.39 Cr. as of 08/06/2026.
What is the current P/E ratio of Sun Pharmaceutical Industries?
The P/E ratios of Sun Pharmaceutical Industries is 37.18 as of 08/06/2026.
What is the current PB ratio of Sun Pharmaceutical Industries?
The PB ratios of Sun Pharmaceutical Industries is 5.12 as of 08/06/2026.
